Skip to main content
. 2022 Aug 17;158(10):1187–1191. doi: 10.1001/jamadermatol.2022.3025

Table 3. Decisional Regret and Last Alopecia Areata (AA) Treatmenta.

Last AA treatment used, No. (%) DRS “I would go for the same choice if I had to do it over again,” No. (%)
Agree Disagree Neutral
Anthralin 28.8 3 (33.3) 4 (44.4) 2 (22.2)
Antimetabolites (such as azathioprine or methotrexate) 21.1 6 (37.5) 2 (12.5) 8 (50.0)
Biologics (such as etanercept or alafacept) 14.1 6 (60.0) 2 (20.0) 2 (20.0)
Calcineurin inhibitors (such as tacrolimus or cyclosporin) 9.9 1 (25.0) 0 3 (75.0)
Decision not to treat at this time 7.0 127 (55.9) 33 (14.5) 67 (29.5)
Immunotherapy (such as DPCP, DNCB, SADBE) 7.0 6 (31.6) 3 (15.8) 10 (52.6)
JAK inhibitors (such as baricitinib, ruxolitinib, tofacitinib) 5.2 79 (74.5) 11 (10.4) 16 (15.1)
Light therapy (such as photodynamic therapy, PUVA, lasers) 1.8 7 (46.7) 5 (33.3) 3 (20.0)
Minoxidil 1.5 25 (33.3) 28 (37.3) 22 (29.3)
Other 1.4 32 (58.2) 10 (18.2) 13 (23.6)
Prostaglandin (such as latanoprost or bimatoprost) 1.0 1 (100) 0 0
Steroid injections 0.8 154 (49.8) 75 (24.3) 80 (25.9)
Sulfasalazine 0.4 0 1 (100) 0
Topical or cream steroids 0.1 28 (37.3) 19 (25.3) 28 (37.3)
Wig 0.1 71 (46.7) 36 (23.7) 45 (29.6)

Abbreviations: DRS, Decisional Regret Scale; DNCB, dinitrochlorobenzene; DPCP, topical diphencyprone; JAK, Janus kinase; SADBE, squaric acid dibutyl ester; PUVA, psoralen and ultraviolet light A.

a

Statistically significant at P < .001.